Ayala Pharmaceuticals (ADXS) Competitors $0.11 +0.08 (+250.33%) As of 02/21/2025 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ADXS vs. IMCC, SYRS, AEZS, GRI, SONN, PRTG, UPXI, GTBP, ADIL, and PLRZShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include IM Cannabis (IMCC), Syros Pharmaceuticals (SYRS), Aeterna Zentaris (AEZS), GRI Bio (GRI), Sonnet BioTherapeutics (SONN), Portage Biotech (PRTG), Upexi (UPXI), GT Biopharma (GTBP), Adial Pharmaceuticals (ADIL), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. IM Cannabis Syros Pharmaceuticals Aeterna Zentaris GRI Bio Sonnet BioTherapeutics Portage Biotech Upexi GT Biopharma Adial Pharmaceuticals Polyrizon IM Cannabis (NASDAQ:IMCC) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings. Do insiders and institutionals believe in IMCC or ADXS? 7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor IMCC or ADXS? IM Cannabis received 6 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 42.86% of users gave IM Cannabis an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIM CannabisOutperform Votes642.86% Underperform Votes857.14% Ayala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes73100.00% Which has more risk & volatility, IMCC or ADXS? IM Cannabis has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Does the media prefer IMCC or ADXS? In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than IM Cannabis. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score. Company Overall Sentiment IM Cannabis Neutral Ayala Pharmaceuticals Neutral Is IMCC or ADXS more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. Ayala Pharmaceuticals' return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-25.55% -129.86% -23.63% Ayala Pharmaceuticals N/A N/A N/A Which has stronger earnings and valuation, IMCC or ADXS? IM Cannabis has higher revenue and earnings than Ayala Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$36.15M0.13-$7.04M-$3.41-0.61Ayala Pharmaceuticals$10K448.04-$48.07M-$7.98-0.01 SummaryIM Cannabis and Ayala Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.48M$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.016.1326.4618.81Price / Sales448.04314.26449.1576.64Price / CashN/A67.8344.0437.47Price / Book-0.056.747.634.64Net Income-$48.07M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.02%-1.82%-2.63%1 Month PerformanceN/A-1.54%0.22%-2.37%1 Year Performance-89.16%-3.14%17.49%13.65% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.11+250.3%N/A-89.2%$1.28M$3.24M-0.0120Analyst ForecastGap UpIMCCIM Cannabis0.4534 of 5 stars$2.25+1.8%N/A-6.7%$5.02M$51.39M-0.66340Positive NewsSYRSSyros Pharmaceuticals4.243 of 5 stars$0.19+1.3%$3.33+1,701.8%-97.5%$4.96M$9.94M-0.06120AEZSAeterna ZentarisN/A$2.76-2.5%N/A-61.4%$4.95M$2.37M-0.1920Analyst ForecastNews CoverageGRIGRI Bio2.3672 of 5 stars$0.55+1.9%$11.50+1,990.9%-96.7%$4.91MN/A0.001Stock SplitNews CoverageSONNSonnet BioTherapeutics1.377 of 5 stars$1.59+3.2%$20.00+1,157.9%-13.8%$4.85M$20,000.000.0010PRTGPortage Biotech0.0827 of 5 stars$4.61-4.8%N/A-46.0%$4.84MN/A-0.116Upcoming EarningsGap DownUPXIUpexi0.7097 of 5 stars$3.90-2.5%N/A-80.4%$4.84M$26M0.00130Earnings ReportGTBPGT Biopharma2.9358 of 5 stars$2.14-4.5%$11.00+414.0%-47.6%$4.77MN/A0.008Negative NewsGap UpADILAdial Pharmaceuticals2.8183 of 5 stars$0.74-5.9%$8.00+979.3%-16.4%$4.75MN/A0.0020PLRZPolyrizonN/A$1.13+0.6%N/AN/A$4.72MN/A0.00N/AGap Down Related Companies and Tools Related Companies IM Cannabis Alternatives Syros Pharmaceuticals Alternatives Aeterna Zentaris Alternatives GRI Bio Alternatives Sonnet BioTherapeutics Alternatives Portage Biotech Alternatives Upexi Alternatives GT Biopharma Alternatives Adial Pharmaceuticals Alternatives Polyrizon Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
